 |
|
Sign in to view your progression
|
|
ON-DEMAND
KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer
|
|
|
ON-DEMAND
Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
|
|
|
ON-DEMAND
Results of the Avoiding Late Diagnosis of Ovarian Cancer (ALDO) Project; a pilot national surveillance program for BRCA mutation-carriers
|
|
|
ON-DEMAND
Results of NSGO-OV-UMB1/ENGOT-OV30 study: A phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)
|
|
Trending Content
{{ help_message }}
{{filter}}
